Can-Fite BioPharma ( (CANF) ) has issued an update.
On April 17, 2025, Can-Fite BioPharma announced that its drug Namodenoson has received FDA approval for compassionate use in treating pancreatic carcinoma, leading to increased interest from U.S. medical centers seeking authorization for their patients. This milestone highlights Namodenoson’s potential in oncology, with ongoing trials in Israel for advanced pancreatic adenocarcinoma and its designation as an Orphan Drug by the FDA, indicating promising therapeutic prospects.
Spark’s Take on CANF Stock
According to Spark, TipRanks’ AI Analyst, CANF is a Neutral.
The overall score of 42 reflects significant financial challenges, including persistent losses and negative cash flows. Technical indicators suggest a bearish trend, and valuation metrics are unattractive due to negative earnings. The absence of earnings call highlights and corporate events adds uncertainty, necessitating strategic improvements for investor confidence.
To see Spark’s full report on CANF stock, click here.
More about Can-Fite BioPharma
Can-Fite BioPharma Ltd. is a biotechnology company focused on developing small molecule drugs targeting oncological and inflammatory diseases. The company is advancing its lead drug candidates, including Namodenoson, which is being evaluated for various cancers and liver diseases, and Piclidenoson, which is in trials for psoriasis. Can-Fite’s drugs aim to address significant markets in cancer, liver, and inflammatory diseases.
YTD Price Performance: -31.28%
Average Trading Volume: 283,632
Technical Sentiment Signal: Buy
Current Market Cap: $15.32M
Learn more about CANF stock on TipRanks’ Stock Analysis page.